Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy for STE-MI
Advertisements

Chapter 3 for 12 Lead Training -Precourse-
Presented by: Fahim H. Jafary, M.D., F.A.C.C. Associate Professor of Medicine Aga Khan University Hospital, Karachi March 14, 2008 Primary Percutaneous.
Regional AMI Care: Bridging the Rural Health Care Gap Darren B. Bean, MD University of Wisconsin Emergency Medicine/Medflight Director UW Level 1 Heart.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
“ If physicians would read two articles per day out of the six million medical articles published annually, in one year, they would fall 82 centuries behind.
Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for STEMI: The Mayo Clinic Protocol Henry H. Ting, MD, MBA Associate Professor of.
Update on the Medical Management of Acute Coronary Syndrome.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
CRITICAL/CLINICAL PATHWAYS ACUTE CORONARY SYNDROMES
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
STEMI: What’s the Rush? STEMI: What’s the Rush? William Phillips, MD, FACC, FSCAI Director of Cardiology CMMC A PCI Center perspective.
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Primary PCI Treatment of choice for Acute MI.
Time Is Myocardium and the Wavefront of Necrosis CM Gibson 2002.
GUSTO I GUSTO I Median Time (hrs) Between Symptom Onset and Treatment GUSTO III GUSTO III InTIME II InTIME II ASSENT.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
Ten Points to Remember from the 2007 STEMI Guideline Update Based on the 2007 Focused Update of the 2004 Guidelines for the Management of Patients With.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ACS and Thrombosis in the Emergency Setting
AMI Strategy How to Achieve Door-to-Balloon Times of 90 Minutes and What to Do Next? Aaron Kugelmass, MD Director, Cardiac Cath Lab Associate Division.
A modern thrombolysis service is superior to primary angioplasty
Acute STEMI: current approach
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
ACTION Registry-GWTG Results: January 1, 2009 – December 31, 2009.
Management Of AMI Does time matter?? What is the best strategy: PPCI Vs TT.
Background Fibrinolytic Rx in STEMI is limited by inadequate reperfusion and/or reocclusion in ~25% of pts. An occluded infarct-related artery is associated.
Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Facilitated PCI: Use of Lytics in the ED Delayed PCI “The Rock Rokos” Lytics “Italian Stallion Hollander”
Update of 2013 ACCF/AHA Guidelines for STEMI Junbo Ge MD,FACC,FESC,FSCAI Zhongshan Hospital, Fudan University.
Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Antiplatelet Interventions in Acute Coronary Syndromes.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
LESSON 1 LESSON 1 Establishment of:
Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.
Door to Balloon Time: Does it Matter? Tale of Two Studies.
Dallas 2015 TFQO: Karen Woolfrey #COI 261 EVREV 1: Karen Woolfrey # COI 261 EVREV 2: Daniel Pichel #COI 513 Taskforce: ACS ACS 872: Pre-hospital Diversion.
1 An Evidence-Based Approach to STEMI: The Emergency Department Perspective Charles V Pollack, Jr, MA, MD, FACEP, FAAEM Professor and Chairman, Emergency.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
S. Chiu Wong MD, FACC Associate Professor of Medicine Weill Medical College of Cornell University Director, Cardiac Catheterization Laboratories The New.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2007 Focused Update of the ACC/AHA 2004 Guidelines.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
For the HORIZONS-AMI Investigators
Ischaemic Heart Disease Acute Coronary Syndrome
The following slides highlight a discussion and analysis of presentations in the Late-Breaking Clinical Trials session from the 55th Annual Scientific.
The following slides highlight a report on a presentation at a symposium and the late-breaking trials session at the American College of Cardiology 53rd.
STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES
Section F: Clinical guidelines
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
% Heparin + GPI IIb/IIIa Bivalirudin +
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
American College of Cardiology Presented by Dr. Michel R. Le May
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Appropriate Use of Lytics: Adherence to the Guidelines Appropriate Use of Lytics: Adherence to the Guidelines W. Frank Peacock, MD, FACEP Vice Chief of Research Department of Emergency Medicine Cleveland Clinic Chagrin Falls, OH

Appropriate Use of Lytics: Adherence to the Guidelines W. Frank Peacock, MD, FACEP Vice Chief Emergency Department The Cleveland Clinic

ST-segment Elevation Spectrum of Acute Coronary Syndromes Ischemic Discomfort at Rest Unstable Angina (UA) Non-Q-wave MI (NSTEMI) Q-wave MI (STEMI) No ST-segment Elevation – ++ + Cardiac Markers Presentation Emergency Department In-hospital 6-24 hours Adapted from Braunwald E, et al. Available at:

Class I Recommendation All STEMI patients should undergo rapid evaluation for reperfusion therapy and have a reperfusion strategy implemented promptly after contact with the medical system. (Level of Evidence: A) Reperfusion Therapy Antman EM, et al. Available at: Accessed November 1, Medical system goal is to facilitate rapid recognition and treatment of patients with STEMI such that door-to-needle (or medical contact–to-needle) time for initiation of fibrinolytic therapy can be achieved within 30 minutes or that door-to- balloon (or medical contact–to-balloon) time for PCI can be kept within 90 minutes.

ED Management

Not critical CDU, d/c? Cath lab?

STEMI: Brief Physical Exam in the Emergency Department Airway, Breathing, Circulation (ABC) Vital signs, general observation Presence or absence of jugular venous distension Pulmonary auscultation for rales Cardiac auscultation for murmurs or gallops Presence or absence of stroke Presence or absence of pulses Presence or absence of systemic hypoperfusion (cool, clammy, pale/ashen) Antman EM, et al. Available at: Accessed November 1, 2005.

STEMI: Acute Medical Therapy General treatment measures Antman EM, et al. Available at: Accessed November 1, Analgesics Nitrates Oxygen β-blockers (decrease heart rate) Primary PCI or coronary thrombolysis (primary PCI preferred after 3 hours) Aspirin ( mg, acute dose) Heparin If PCI: – Clopidogrel – GP IIb/IIIa inhibitors Infarct size limitation Reperfusion Antithrombotic and antiplatelet therapy

Goal of Fibrinolytic Therapy Alone: Open Arteries and Reduce Mortality Ross AM, et al. Circulation. 1998;97: min TIMI Flow Post-fibrinolytic GUSTO-I (STK vs t-PA) Angiographic Investigators: Post-lytic TIMI Flow Predicts Mortality

Pharmacologic Reperfusion Available Resources Class I Recommendations STEMI patients presenting to a facility without the capability for expert, prompt intervention with primary PCI within 90 minutes of first medical contact should undergo fibrinolysis unless contraindicated (Level of Evidence: A) Antman EM, et al. J Am Coll Cardiol. Available at: Accessed November 1, 2005.

STEMI: Transfer Status PTCA NRMI ( ) Door-to-balloon times for primary PTCA patients, by primary transfer status. Gibson, CM Am Heart J 2004;148:S29–33. NRMI 1NRMI 2NRMI 3 NRMI 4 NRMI transfer-in patients NRMI non-transfer-in patients

Nallamothu BK et al. Circulation 2005;111: STEMI: Transfer for PCI NRMI ( ) 4,278 patients Door-to-balloon time% of patients <90 min4.2 <2 h h55.4 >4 h

ACC/AHA STEMI Guidelines: Primary Percutaneous Coronary Intervention Class I Recommendations If immediately available, primary PCI should be performed: –In patients with STEMI (including true posterior MI) or MI with new or presumably new LBBB within 12 hours of symptom onset; –In a timely fashion (balloon inflation within 90 minutes); –By persons skilled in the procedure (>75 PCI procedures per year). The procedure should be supported by: –Experienced personnel; –An appropriate laboratory environment (> 200 PCI procedures per year, of which > 36 are primary PCI for STEMI); and –Cardiac surgery backup. (Level of Evidence: A) Antman EM, et al. J Am Coll Cardiol. Available at:

ACC/AHA STEMI Guidelines: Primary Percutaneous Coronary Intervention Class I Recommendations Level of Evidence: B –Primary PCI should be performed as quickly as possible (goal of medical contact-to-balloon or door-to-balloon time < 90 minutes). –If the symptom duration is within 3 hours and the expected door-to-balloon time minus the expected door-to-needle time is: Within 1 hour, primary PCI is generally preferred. Greater than 1 hour, fibrinolytic therapy (fibrin-specific agents) is generally preferred. –If symptom duration is greater than 3 hours, primary PCI is generally preferred. Antman EM, et al. J Am Coll Cardiol. Available at:

In-hospital Mortality vs Door to Balloon Time Door to Balloon Time (hours) In-hosp Death Rate >3.0 N= 2,322 Brodie BR, JACC 47, 2006 N=384N=493N=750N=673

7 year Mortality vs Door to Balloon Time Door to Balloon Time (hours) 7 year Death Rate >3.0 N= 2,322 Brodie BR, JACC 47, 2006 N=384 N=493N=750N=673

Primary PCI vs Thrombolysis in STEMI: Meta-analysis (23 RCTs, N=7739) Adapted with permission from Keeley EC, et al. Lancet. 2003;361: PCI Thrombolytic therapy Frequency (%) Short-term Outcomes (4-6 weeks) Death P =.0002 Nonfatal MI P <.0001 Recurrent Ischemia P <.0001 Hemor- rhagic Stroke P <.0001 Major Bleed P =.032 Death, Nonfatal Reinfarction, or Stroke P <.0001 Bonferroni correction 6 variables: p <0.0083

PCI-Related Time Delay (door-to-balloon, door to-needle) Circle sizes =sample size of the individual study. Solid line=weighted meta-regression. For every 10 min delay to PCI: 1% reduction in mortality difference vs lytics Nallamothu BK, Bates ER. Am J Cardiol. 2003:92:824 Favors PCI Favors Lysis P = min Absolute Risk Difference in Death (%) Mortality With 1° PCI Vs Time

Valentines Day Massacre Keely EC, Boura JA, Grines CL. Feb 14, 2006, Lancet

PCI vs Faciliated PCI: Meta-analysis 17 STEMI trials Received either –Primary PCI (N=2267) –Facilitated PCI N=2237) Short term outcomes (< 42 days) –Death, CVA, non-fatal re-MI –Urgent TVR, re-bleed Keely EC, Boura JA, Grines CL. Lancet, 2006

Facilitated PCI Meta-analysis f-PCI (%)PCI (%)OR (95% CI) Initial TIMI (2.22, 4.45) Final TIMI (0.88, 1.64) Death (1.01, 1.87) Urgent TVR (1.23, 4.66) ICH0.70.1P= Keely EC, Boura JA, Grines CL. Lancet, 2006

Facilitated PCI Meta-analysis Conclusions “Facilitated PCI offers no benefit over primary PCI and should not be used outside of the context of randomized clinical trials” Furthermore, facilitated interventions with thrombolytic based regimens should be avoided.

Time Dependency?

NRMI 2,3,4 452,544 Reperfusion Eligible STEMI Patients 1963 Hospitals Transfer Out Patients n=119,235 Missing Time Intervals n=13,137 Did Not Receive PCI or Fibrinolytic Therapy as Initial Reperfusion n=89,524 Study Population 192,509 Patients 645 Hospitals 230,648 Patients 1860 Hospitals ≥20 STEMI Patients Treated Treatment of ≥10 Patients With Primary PCI and ≥10 Patients With Fibrinolytic Therapy CM Gibson Pinto DS, et al. Circulation. 2006;114: Implications of Hospital Delays for Selection of Reperfusion Strategy in STEMI

Pre-hospital Delay (Min) <65 years and Anterior Infarction <65 years and Non-anterior Infarction ≥65 years and Anterior Infarction ≥65 years and Non-anterior Infarction min Met goal w/o transfer: 2.6% Met goal w/ transfer: 3.6% (n=19,517 pts; n=269 hospitals) 56 min Met goal w/o transfer: 20.2% Met goal w/ transfer: 17.3% (n=19,517 pts; n=269 hospitals) 109 min Met goal w/o transfer: 94.1% Met goal w/ transfer: 92.8% (n=9,812 pts; n=180 hospitals) 154 min Met goal w/o transfer: 99.8% Met goal w/ transfer: 100.0% ( n=20,424 pts; n=271 hospitals) min Met goal w/o transfer: 7.9% Met goal w/ transfer: 11.9% (n=5,296 pts; n=117 hospitals) 103 min Met goal w/o transfer: 89.1% Met goal w/ transfer: 82.2% (n=16,119 pts; n=244 hospitals) 142 min Met goal w/o transfer: 98.1% Met goal w/ transfer: 97.1% (n=3,739 pts; n=91 hospitals) 183 min Met goal w/o transfer: 100.0% Met goal w/ transfer: 100.0% (n=10,614 pts; n=191 hospitals) Time at Which PCI Loses Superiority in Survival Over Fibrinolysis Varies by Patient Risk CM Gibson Pinto DS, et al. Circulation. 2006;114:

Question&Answer

Thank You! Please make sure to hand in your evaluation and pick up a ClinicalTrialResults.org flash drive